Enovis Raises 2026 Outlook After Q3 Sales Rise to $559M

Dallas-based medical technology company Enovis Corporation reported third-quarter net sales of $558.7 million on Thursday, up 1.8% from $548.9 million a year earlier and about 5% on an organic basis, according to its results release carried on Nasdaq and summarized by 24/7 Wall St.

• Net sales: $558.7 million, up 1.8% as reported
• Organic sales growth: about 5%, after excluding foreign exchange and the October 2025 Dr. Comfort Footcare Solutions divestiture
• GAAP net income attributable to Enovis: $3.1 million, or $0.06 a share on a consolidated basis ($0.02 from continuing operations)
• Adjusted EPS (non-GAAP): $0.88, up from $0.75
• Adjusted EBITDA: about $104 million, or 18.5% of sales, versus 17.3% a year earlier
• Gross margin: 60.8%, up from 59.9%

Reconstructive sales rose 6% on both a reported and organic basis to $273.3 million, led by international Reconstructive growth of 7%. Prevention & Recovery sales fell 1.9% as reported to $285.4 million but rose 3% organically, with U.S. bracing and support up 4.5%, the company said. Chief Executive Damien McDonald said growth matched expectations, with share gains in Reconstructive and steady Prevention & Recovery results, while citing volatility and cost inflation in many markets.

Guidance and $200 million buyback

Enovis raised full-year 2026 adjusted EBITDA guidance to $428 million to $438 million from $425 million to $435 million and lifted adjusted EPS guidance to $3.58 to $3.79 from $3.52 to $3.73. It narrowed revenue guidance to $2.32 billion to $2.35 billion from $2.31 billion to $2.37 billion and now embeds about 5% organic revenue growth. Free cash flow conversion is expected at 25% or higher.

The board approved a new share repurchase authorization of up to $200 million, replacing the prior $100 million program. Timing and amounts will depend on market conditions and capital priorities, Enovis said. Management also pointed to its planned acquisition of eCential Robotics and ongoing Lima integration costs among items excluded from adjusted results. An investor call was set for 8:30 a.m. Eastern on Thursday.

Enovis joins other U.S. health-care suppliers reporting this week, including Cardinal Health’s fiscal first-quarter outlook raise.

Sources: Enovis, Nasdaq company release, 24/7 Wall St.